---

GROUP-B: Community Medicine — Model Answers

---

Q1. Danger Signals of Cancer | Epidemiology of Breast Cancer | Levels of Prevention

A. Danger Signals of Cancer (CAUTION mnemonic)

---

B. Epidemiology of Breast Cancer

• Most common cancer in women worldwide; accounts for ~25% of all female cancers
• Age-standardized incidence: ~47/100,000 women globally
• Higher incidence in developed countries (North America, Northern Europe) vs. developing nations
• Mortality highest in low-income countries due to late-stage diagnosis

• Leading female cancer (surpassing cervical cancer since ~2010)
• Incidence ~25.8/100,000 women (urban > rural)
• Peak age: 45–55 years (younger than Western women — peak 60–65 yrs in West)
• ~30% of female cancers in metropolitan cities (Mumbai, Delhi)
• 5-year survival: ~60% overall; ~90% if detected at Stage I

• Person: Women; risk increases with age; BRCA1/BRCA2 mutation carriers; higher in upper socioeconomic class
• Place: Urban > rural; North America and Europe > Asia/Africa (but Asia incidence rising rapidly)
• Time: Incidence rising globally; attributed to changing lifestyle, delayed childbearing, increased HRT use

---

C. Modes of Intervention — Levels of Prevention

1. Primordial Prevention

• Prevent conditions (lifestyle, social norms) that lead to risk factors
• Promote healthy body weight from childhood
• Discourage sedentary behavior and unhealthy diet at population level
• Health education via schools and mass media

2. Primary Prevention (Reduce Incidence)

• Lifestyle modification: Maintain healthy BMI; reduce alcohol consumption; avoid exogenous estrogens unnecessarily
• Breastfeeding promotion: Reduces risk (longer duration = greater protection)
• Physical activity: ≥150 min/week moderate activity
• Chemoprevention: Tamoxifen/raloxifene for high-risk women (BRCA carriers)
• Prophylactic surgery: Bilateral mastectomy in BRCA1/2 mutation carriers (high-risk only)
• Avoid prolonged HRT: Particularly combined estrogen-progestin therapy

3. Secondary Prevention (Early Detection)

• Breast Self-Examination (BSE): Monthly, 7–10 days after menstrual period; all women >20 years
• Clinical Breast Examination (CBE): Every 3 years for 20–40 age group; annually after 40
• Mammography:
  • Annual for women ≥40 years (USPSTF: 40–74 years)
  • Gold standard screening tool; sensitivity ~75–85%
  • FNAC / biopsy for suspicious lesions
• Ultrasonography: For dense breasts; younger women
• MRI: For BRCA1/2 carriers or very high-risk women
• National Cancer Screening Programme (India): NPCDCS — CBE-based screening at subcentre level

4. Tertiary Prevention (Reduce Disability/Death)

• Prompt surgery (lumpectomy/mastectomy), radiotherapy, chemotherapy, hormone therapy
• Palliative care and pain management in advanced cases
• Rehabilitative services: prosthetics, physiotherapy, psychosocial support
• Cancer registries and follow-up surveillance

---

Q2. Risk Factors for Breast Cancer | Cancer Screening | Cancer Registry

A. Risk Factors for Breast Cancer

• Female sex, advancing age (>40 yrs)
• Family history: first-degree relative with breast cancer doubles the risk
• Genetic mutations: BRCA1 (chromosome 17q), BRCA2 (chromosome 13q)
• Early menarche (<12 years), late menopause (>55 years) — prolonged estrogen exposure
• Nulliparity or first full-term pregnancy after 30 years
• Previous breast cancer or LCIS/DCIS
• Dense breast tissue
• Exposure to ionizing radiation (especially chest radiation in adolescence)

• Obesity/overweight (postmenopausal women — adipose tissue as estrogen source)
• Sedentary lifestyle
• Alcohol consumption (risk increases linearly; >2 drinks/day: RR ~1.5)
• Exogenous hormones: prolonged HRT, oral contraceptives (slight increase)
• No breastfeeding
• High dietary fat intake

---

B. Cancer Screening

1. The condition must be an important health problem
2. There must be an acceptable treatment
3. Facilities for diagnosis and treatment must be available
4. Recognizable latent or early symptomatic stage must exist
5. Suitable test must exist (sensitive, specific, acceptable, safe, cheap)
6. Natural history of the condition must be understood

• Screening for oral, breast, and cervical cancers at community level through ASHAs and ANMs
• VIA (Visual Inspection with Acetic Acid) for cervical cancer
• CBE for breast cancer
• Oral cavity examination for oral cancer

---

C. Cancer Registry

• NCRP (National Cancer Registry Programme) established in 1981 under ICMR
• Major PBCRs: Bangalore, Mumbai, Chennai, Delhi, Bhopal, Barshi (rural)
• Data published in "Cancer Incidence in Five Continents" (IARC/WHO)

1. Provides incidence, prevalence, mortality data
2. Identifies high-risk groups and areas
3. Evaluates cancer control programs
4. Helps plan health resources
5. Epidemiological research and etiological studies
6. Monitors time trends in cancer burden

---

Q3. Reduced Distance Vision in Children Under 12 — Management as BMOH

Background

Assessment (Rapid Situation Analysis)

1. Collect data: Review school health records; conduct rapid survey across schools in the block
2. Magnitude estimation: Estimate prevalence; define affected age groups and areas
3. Cause identification: Rule out nutritional causes (Vitamin A deficiency — causes night blindness primarily, not myopia; however assess nutritional status), genetic predisposition, environmental factors (increased near-work, reduced outdoor activity)

Management Steps as BMOH

Step 1: Immediate Measures

• School Health Services activation: Direct PHC medical officers to conduct vision screening camps in all schools of the block
• Screening tool: Snellen's chart at 6 meters; children who fail referred for detailed refraction
• Referral: Children with confirmed myopia referred to District Hospital / ophthalmologist for prescription glasses

Step 2: Corrective Action

• Provision of corrective spectacles (Rashtriya Bal Swasthya Karyakram — RBSK scheme provides glasses free to school children)
• Coordinate with RBSK teams (Mobile Health Teams) to screen and distribute spectacles
• Teachers counselled about seating arrangements (myopic children seated in front rows)

Step 3: Nutritional Assessment

• Screen for Vitamin A deficiency (though this causes xerophthalmia/night blindness, not myopia; rule out)
• Promote dietary diversity; ensure mid-day meals include vitamin A-rich foods

Step 4: Health Education

• Educate parents and teachers: limit screen time, adequate lighting while studying, 20-20-20 rule
• Promote outdoor activity (at least 1–2 hours/day — protective against myopia progression)
• Awareness about the importance of annual eye check-ups

Step 5: Reporting and Surveillance

• Report findings to District Health Officer
• Update registers; monitor prevalence annually
• Coordinate with School Education Department for follow-up

Step 6: Preventive Measures

• Integration of vision screening into annual school health check-up as per School Health Programme
• IEC (Information Education Communication) campaigns
• Advocate for adequate classroom lighting standards

Relevant Government Programmes

• RBSK (Rashtriya Bal Swasthya Karyakram): Screens 0–18 years for 4 Ds — Defects at birth, Diseases, Deficiencies, Developmental delays including vision defects
• National Programme for Control of Blindness and Visual Impairment (NPCBVI): Provides support for school eye screening

---

Q4. Early Signs of Cancer | Epidemiology of Oral Cancer | Primary Prevention

A. Early Signs of Cancer

1. Leukoplakia — White patch on oral mucosa that cannot be scraped off; premalignant
2. Erythroplakia — Red velvety patch; higher malignant potential than leukoplakia
3. A non-healing ulcer — Persistent ulcer >2 weeks that does not respond to treatment
4. Unexplained bleeding — Blood in sputum, urine, stool, or from nipple/vagina
5. Unexplained lump or swelling — Painless lymphadenopathy, breast lump, neck mass
6. Persistent hoarseness or change of voice
7. Difficulty swallowing (dysphagia) — early esophageal/pharyngeal cancer
8. Unexplained weight loss (>10% body weight in 6 months)
9. Change in bowel or bladder habits
10. Persistent nagging cough unresponsive to treatment
11. Change in a wart or mole (ABCDE criteria: Asymmetry, Border, Color, Diameter, Evolution)
12. Unexplained anemia — especially in elderly men (suspect GI malignancy)

---

B. Epidemiology of Oral Cancer

• 8th most common cancer globally; >375,000 new cases/year
• Male > Female (2:1 to 4:1 ratio)
• Age: predominantly 40–70 years; rare before 40

• India accounts for ~1/3 of global oral cancer burden
• One of the top 3 cancers in India (along with breast and cervical cancer)
• Incidence: ~20/100,000 in males; constitutes ~30% of all cancers in men
• Highest incidence in states: Bihar, Rajasthan, Uttar Pradesh, Assam
• High burden due to widespread tobacco use (smoking + smokeless forms)

• Person: Males > females; low socioeconomic class; rural > urban
• Site: Buccal mucosa most common in India (due to chewing tobacco); tongue most common globally
• Place: South and Southeast Asia; India, Pakistan, Bangladesh, Sri Lanka (tobacco belt)
• Time: Incidence rising in younger age groups; associated with HPV (especially oropharyngeal)

• Tobacco (smoking + smokeless): accounts for >80% of oral cancers in India
  • Betel quid with tobacco (pan masala, gutka), bidi, cigarette
• Alcohol: Synergistic effect with tobacco (risk multiplies)
• Betel nut (areca nut): Independent carcinogen; causes Oral Submucous Fibrosis (OSMF)
• HPV infection: HPV-16 and HPV-18 (oropharyngeal cancers)
• Poor oral hygiene, sharp dental edges
• Nutritional deficiencies: Iron, riboflavin, Vitamin A
• Premalignant conditions: leukoplakia, erythroplakia, OSMF, lichen planus

---

C. Primary Prevention of Oral Cancer

1. Tobacco Control:
   • Tobacco cessation programmes; Tobacco Quit lines (1800-112-356 in India)
   • COTPA (Cigarettes and Other Tobacco Products Act, 2003): Ban on advertising; pictorial warnings on packs; smoke-free public places
   • NTCP (National Tobacco Control Programme): District-level tobacco cessation centers
   • Ban on gutka and pan masala in several states
2. Alcohol Reduction:
   • Legislation restricting alcohol sale and advertising
   • Public awareness about risk of combined tobacco + alcohol use
3. Betel Nut/Pan Masala Restriction:
   • State-level bans on areca nut products
   • Health education about OSMF risk
4. HPV Vaccination:
   • Vaccine against HPV-16, HPV-18 reduces risk of oropharyngeal cancers
   • Recommended for adolescent girls and boys before sexual debut
5. Nutritional Improvement:
   • Promote diet rich in fruits and vegetables (antioxidants — beta-carotene, Vitamin C, E)
   • Address iron and riboflavin deficiencies
6. Health Education and IEC:
   • Awareness through mass media, schools, community health workers
   • Training ASHAs/ANMs to counsel against tobacco use
7. Oral Hygiene Promotion:
   • Regular dental checkups
   • Removal of chronic irritants (sharp teeth, ill-fitting dentures)
8. Legislation and Policy:
   • Workplace smoking bans
   • Minimum legal age for tobacco purchase
   • Taxation on tobacco products

---

Q5. Classification of Diabetes | Risk Factors | Diagnostic Criteria

A. Classification of Diabetes Mellitus (WHO/ADA)

1. Type 1 Diabetes Mellitus (T1DM)

• Absolute insulin deficiency due to autoimmune destruction of β-cells
• HLA-DR3, HLA-DR4 association
• Usually presents in youth (<30 years)
• Prone to diabetic ketoacidosis (DKA)
• Requires lifelong insulin therapy

2. Type 2 Diabetes Mellitus (T2DM)

• Insulin resistance + progressive β-cell dysfunction
• Most common type (~90–95% of all DM)
• Strong association with obesity, sedentary lifestyle
• Usually presents after 40 years (but increasingly younger)
• Managed with lifestyle modification + oral hypoglycaemics ± insulin

3. Gestational Diabetes Mellitus (GDM)

• Any degree of glucose intolerance first recognized during pregnancy
• Usually resolves postpartum; increases risk of future T2DM (7× higher)
• Screened at 24–28 weeks gestation (OGTT)

4. Other Specific Types

• Genetic defects of β-cell function: MODY (Maturity Onset Diabetes of the Young) — Types 1–6
• Genetic defects in insulin action: Type A insulin resistance, Leprechaunism
• Diseases of exocrine pancreas: Pancreatitis, cystic fibrosis, hemochromatosis
• Endocrinopathies: Cushing's syndrome, acromegaly, pheochromocytoma, glucagonoma
• Drug/chemical induced: Glucocorticoids, thiazides, β-blockers, tacrolimus, atypical antipsychotics
• Infections: Congenital rubella, CMV
• Uncommon immune-mediated: Stiff-man syndrome, anti-insulin receptor antibodies

---

B. Risk Factors for Diabetes (T2DM)

• Age >45 years
• Family history of diabetes (first-degree relative)
• Genetic predisposition; certain ethnicities (South Asian, African American, Hispanic)
• History of GDM or delivery of baby >4 kg
• Polycystic Ovarian Syndrome (PCOS)
• Previous Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT)

• Obesity (BMI >25, especially central obesity — waist circumference ≥90 cm men, ≥80 cm women in South Asians)
• Physical inactivity
• Unhealthy diet: High calorie, high fat, refined carbohydrates; low fiber
• Hypertension (BP ≥140/90 mmHg)
• Dyslipidemia (HDL <35 mg/dL; triglycerides >250 mg/dL)
• Smoking
• Stress and sleep deprivation
• Metabolic syndrome

---

C. Diagnostic Criteria Using Blood Sugar Levels (ADA 2024 / WHO Criteria)

Current ADA/WHO Diagnostic Categories:

• Fasting = no caloric intake for ≥8 hours
• In the absence of symptoms, diagnosis requires two abnormal test results (either two separate tests on different days, or two different tests on the same day)
• In the presence of classic symptoms (polyuria, polydipsia, unexplained weight loss) + random plasma glucose ≥200 mg/dL = diagnosis confirmed without repeat

WHO Criteria (used in India/community settings):

• FPG ≥126 mg/dL OR
• 2-hr post-load glucose ≥200 mg/dL (75g OGTT)
• These must be confirmed on a second occasion (unless symptomatic)

Oral Glucose Tolerance Test (OGTT) — Standard Method:

1. Fasting blood sample taken
2. Patient given 75g anhydrous glucose dissolved in 250–300 mL water, orally
3. Blood sample taken at 2 hours
4. Interpret as per table above

Gestational Diabetes (IADPSG/WHO 2013 criteria):

• One abnormal value on 75g OGTT is sufficient for GDM diagnosis

---

Key mnemonics:

• Cancer danger signals: CAUTION
• Oral cancer risk: TAB — Tobacco, Alcohol, Betel nut
• DM diagnosis: FPG ≥126 / 2hr ≥200 / HbA1c ≥6.5 / Random ≥200 + symptoms